T
Tom M. Ganten
Researcher at University Hospital Heidelberg
Publications - 76
Citations - 3401
Tom M. Ganten is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Sorafenib & Liver transplantation. The author has an hindex of 26, co-authored 76 publications receiving 3014 citations. Previous affiliations of Tom M. Ganten include German Cancer Research Center & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma
Susanne Kleber,Ignacio Sancho-Martinez,B Wiestler,Alexandra Beisel,Christian Gieffers,Oliver Hill,Meinolf Thiemann,Wolf Mueller,Jaromir Sykora,Andreas Kuhn,Nina Schreglmann,Elisabeth Letellier,Cecilia Zuliani,Stefan Klussmann,Marcin Teodorczyk,Hermann Josef Gröne,Tom M. Ganten,Holger Sültmann,Jochen Tüttenberg,Andreas von Deimling,Anne Régnier-Vigouroux,Christel Herold-Mende,Ana Martin-Villalba +22 more
TL;DR: CD95 is uncovered as an activator of PI3K and, most importantly, as a crucial trigger of basal invasion of glioblastoma in vivo.
Journal ArticleDOI
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Tom M. Ganten,Ronald Koschny,Jaromir Sykora,Henning Schulze-Bergkamen,Peter Büchler,Tobias L. Haas,Manuela B. Schader,Andreas Untergasser,Wolfgang Stremmel,Henning Walczak +9 more
TL;DR: The data show that whereas TRAIL alone or together with selected chemotherapeutic drugs seems to be safe, the combination of TRAIL with cisplatin is toxic to PHH.
Journal ArticleDOI
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs
Tom M. Ganten,Tobias L. Haas,Jaromir Sykora,Jaromir Sykora,Heiko Stahl,Martin R. Sprick,Stefanie C. Fas,Andreas Krueger,M. A. Weigand,Anne Grosse-Wilde,Wolfgang Stremmel,Peter H. Krammer,Henning Walczak +12 more
TL;DR: A potential mechanism for TRAIL sensitisation by 5-FU is the increased effectiveness of caspase-8 recruitment to and activation at the DISC facilitated by the downregulation of cFLIP and the consequent shift in the ratio of casing-8 to c FLIP at theDISC.
Journal ArticleDOI
The promise of TRAIL—potential and risks of a novel anticancer therapy
TL;DR: Most preclinical studies show a high efficiency of a combinatorial TRAIL-based therapy in animal models and in primary human ex vivo tumor cells with a low toxicity in normal cells, compared to the unwanted effects of TRAIL treatment on normal tissue.